42.47
-0.89 (-2.06%)
| Previous Close | 43.36 |
| Open | 44.15 |
| Volume | 199,326 |
| Avg. Volume (3M) | 1,781,237 |
| Market Cap | 7,814,791,168 |
| Price / Earnings (Forward) | 1.00 |
| Price / Sales | 8.01 |
| Price / Book | 6.19 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Legend Biotech Corporation | Bullish | Mixed |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 83.00 (Morgan Stanley, 95.46%) | Buy |
| Median | 76.00 (78.97%) | |
| Low | 54.00 (UBS, 27.16%) | Buy |
| Average | 72.17 (69.95%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 36.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 27 Aug 2025 | 66.00 (55.42%) | Buy | 34.72 |
| JP Morgan | 25 Aug 2025 | 78.00 (83.68%) | Buy | 34.60 |
| Morgan Stanley | 12 Aug 2025 | 83.00 (95.46%) | Buy | 36.99 |
| 10 Jul 2025 | 81.00 (90.75%) | Buy | 39.71 | |
| RBC Capital | 12 Aug 2025 | 77.00 (81.33%) | Buy | 36.99 |
| HC Wainwright & Co. | 17 Jul 2025 | 75.00 (76.62%) | Buy | 42.13 |
| 08 Jul 2025 | 75.00 (76.62%) | Buy | 37.49 | |
| UBS | 02 Jul 2025 | 54.00 (27.16%) | Buy | 35.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Aug 2025 | Announcement | Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference |
| 18 Aug 2025 | Announcement | Legend Biotech Appoints Carlos Santos as Chief Financial Officer |
| 11 Aug 2025 | Announcement | Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights |
| 28 Jul 2025 | Announcement | Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results |
| 03 Jun 2025 | Announcement | Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |